EKSO Files Routine 8-K, Confirms Nasdaq Listing & Registration Details
Ticker: EKSO · Form: 8-K · Filed: Jan 10, 2024 · CIK: 1549084
| Field | Detail |
|---|---|
| Company | Ekso Bionics Holdings, Inc. (EKSO) |
| Form Type | 8-K |
| Filed Date | Jan 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, regulatory-filing, 8-K
TL;DR
**EKSO filed a routine 8-K, no new news, just administrative updates.**
AI Summary
This 8-K filing from Ekso Bionics Holdings, Inc. (EKSO) on January 10, 2024, is a routine administrative update confirming its status as a publicly traded company on the Nasdaq Capital Market under the trading symbol EKSO. It primarily serves to update the company's registration information with the SEC, including its address at 101 Glacier Point, Suite A, San Rafael, California 94901. This filing is largely procedural and does not announce any new financial results, strategic changes, or material events that would directly impact the company's operations or stock value, meaning it's unlikely to cause significant stock movement.
Why It Matters
This filing is a standard administrative update, confirming Ekso Bionics' continued compliance with SEC reporting requirements and its listing on the Nasdaq Capital Market. It provides no new material information that would typically influence an investor's decision.
Risk Assessment
Risk Level: low — This 8-K is purely administrative and does not contain any information that would introduce new risks or change the company's operational risk profile.
Analyst Insight
A smart investor would recognize this as a non-event filing, providing no new material information to warrant any immediate action regarding EKSO stock. It simply confirms ongoing regulatory compliance.
Key Numbers
- $0.001 — par value per share (the stated par value of Ekso Bionics' Common Stock)
- 2024-01-10 — Date of Report (the date the earliest event reported in the 8-K occurred)
- 510-984-1761 — Registrant's telephone number (the business phone number for Ekso Bionics Holdings, Inc.)
Key Players & Entities
- Ekso Bionics Holdings, Inc. (company) — the registrant filing the 8-K
- Nasdaq Capital Market (company) — the exchange where EKSO's common stock is registered
- EKSO (company) — the trading symbol for Ekso Bionics Holdings, Inc.
- 101 Glacier Point, Suite A, San Rafael, California 94901 (dollar_amount) — the business address of Ekso Bionics Holdings, Inc.
- 001-37854 (dollar_amount) — the Commission File Number for Ekso Bionics Holdings, Inc.
FAQ
What is the purpose of this 8-K filing by Ekso Bionics Holdings, Inc.?
This 8-K filing is a 'Current Report Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934' and appears to be a routine administrative update, confirming the company's registration details and its listing on the Nasdaq Capital Market as of January 10, 2024.
What is the trading symbol and exchange for Ekso Bionics Holdings, Inc.?
The filing states that Ekso Bionics Holdings, Inc. trades under the symbol EKSO on the Nasdaq Capital Market, with its Common Stock having a $0.001 par value per share.
What is the business address of Ekso Bionics Holdings, Inc. as reported in this filing?
The business address listed for Ekso Bionics Holdings, Inc. is 101 Glacier Point, Suite A, San Rafael, California 94901.
What is the date of the earliest event reported in this 8-K filing?
The 'Date of Report (date of earliest event reported)' is January 10, 2024.
Does this 8-K filing indicate that Ekso Bionics Holdings, Inc. is an emerging growth company?
The filing includes a section to 'Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions' and also 'Indicate by check mark whether the registrant is an emerging growth company as defined in Rule', but no box is checked for emerging growth company status, implying it is not currently claiming that status in this filing.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-01-10 17:23:43
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value per share EKSO Nasdaq Capi
Filing Documents
- ekso20231218_8k.htm (8-K) — 26KB
- ex_607872.htm (EX-23.1) — 3KB
- 0001437749-24-001129.txt ( ) — 158KB
- ekso-20240110.xsd (EX-101.SCH) — 3KB
- ekso-20240110_def.xml (EX-101.DEF) — 11KB
- ekso-20240110_lab.xml (EX-101.LAB) — 15KB
- ekso-20240110_pre.xml (EX-101.PRE) — 11KB
- ekso20231218_8k_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.   (d) Exhibits.   Exhibit Number   Description       23.1   Consent of WithumSmith+Brown, PC, independent registered public accounting firm       104   Cover Page Interactive Data File (embedded within the Inline XBRL document)        
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.     EKSO BIONICS HOLDINGS, INC. By: /s/  Jerome Wong Name: Jerome Wong Title:        Chief Financial Officer           Dated: January 10, 2024